GlassScriptPhysician profile
Jamshid Mian
NPI 1538143953
$7,061.47
in general payments reported to CMS, 2019-2025
38 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $415 · 2021: $322 · 2022: $1,313 · 2023: $1,644 · 2024: $1,171 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,224.13 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $816.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $485.97 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $363.21 | 2019-2024 | |
| Lilly USA, LLC | $356.62 | 2020-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $335.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $290.14 | 2021-2024 | |
| Glaxosmithkline, LLC. | $266.69 | 2019-2025 | Trelegy Ellipta |
| Silk Road Medical, INC. | $178.18 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Sanofi-Aventis U.S. LLC | $157.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $141.81 | 2019 | |
| Amgen INC. | $140.65 | 2019-2025 | Repatha, Otezla, Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.07 | 2023-2025 | Jardiance |
| Ucb, INC. | $106.48 | 2022-2023 | Cimzia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamshid Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.